Tratamiento farmacológico en pacientes con LES en el Hospital Teodoro Maldonado Carbo entre 2016-2018.

Abstract

Objective: Describe the effects of treatment in patients with systemic lupus erythematosus treated in the Hospital Teodoro Maldonado Carbo during the period 2016-2018. Materials and methods: A retrospective, observational, cross-sectional, descriptive study was conducted in patients who had been treated by the Rheumatology Service of Hospital Teodoro Maldonado Carbo (HTMC) and who were diagnosed with SLE during the period 2016 - 2018. Sociodemographic data, disease activity, hospitalization, and variables related to the drugs used were recorded. For the processing and statistical analysis of the data obtained, the SPSS program was used. Descriptive results were expressed as mean and standard deviation (SD). Results: In the present study, 75 patients with a diagnosis of SLE were analyzed. 60 (80%) patients were female. 21 (28%) patients were hospitalized and 18 (85.71%) were admitted due to disease activity. In relation to drugs, corticosteroids were used by 64 (85.30%) patients and were definitively suspended in 4 (10.67%). Among antimalarials, chloroquine was used in 58 (77.30%) patients and hydroxychloroquine in 30 (40%). Azathioprine, methotrexate, cyclophosphamide, mycophenolate mofetil, rituximab, cyclosporine and acetylsalicylic acid were used in 17 (22.67%), 2 (2.67%), 6 (8%), 49 (65.33) %), 3 (4%), 8 (10.67%) and 8 (10.67%) patients, respectively. Azathioprine was suspended in 9 (47,06%) patients. Conclusion: Disease activity was the most frequent cause of hospitalization. The most used drug was corticoids. There is a greater use of chloroquine than hydroxychloroquine. With regard to immunosuppressive therapy, mycophenolate was the most used. Azathioprine was suspended in most patients.